Evidence map›Paper›PMID 42304646›Full record

ArticleEnvironmental and molecular mutagenesis2026

Evaluation of Type 1 Error Rates in Duplex Sequencing for Mutagenicity Testing Using Vehicle Control Data and Simulation Analyses.

Andrew Williams, Shaofei Zhang, Dingzhou Li, Wen Sun, Maik J Schuler, Francesco Marchetti, Carole L Yauk

Abstract read
In one paragraph

Article in Environmental and molecular mutagenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Andrew WilliamsEnvironmental Health Science and Research Bureau, Health Canada, Ottawa, Ontario, Canada.ORCID 0000-0002-7637-7686
Shaofei ZhangPfizer Worldwide Research, Development, and Medical, Groton, Connecticut, USA.ORCID 0000-0003-0169-4078
Dingzhou LiPfizer Worldwide Research, Development, and Medical, Groton, Connecticut, USA.
Wen SunPfizer Worldwide Research, Development, and Medical, Groton, Connecticut, USA.
Maik J SchulerNonclinical Safety, Bristol Myers Squibb, New Brunswick, New Jersey, USA.
Francesco MarchettiEnvironmental Health Science and Research Bureau, Health Canada, Ottawa, Ontario, Canada.
Carole L YaukDepartment of Biology, University of Ottawa, Ottawa, Ontario, Canada.

Funding

Burroughs Wellcome Fund 1021737Canada Research Chairs CRC-2020-00060
6 · The paper itself

Abstract

Accurate mutation detection and quantification are crucial for understanding mutagenesis and its potential health implications. Traditional in vivo mutagenicity assays, such as the transgenic rodent gene mutation assay, are limited by their focus on single reporter genes and inability to efficiently generate mutation spectra. Error-corrected sequencing (ECS) technologies like Duplex Sequencing (DS) offer significant advantages, including extremely low error rates and the ability to measure mutation frequencies (MFs) across various tissues and model organisms. Before ECS approaches can be adopted for regulatory purposes, their performance characteristics, particularly the type 1 error rate, must be rigorously established. We evaluated the type 1 error rate of DS through empirical analysis of vehicle control data and complementary simulation studies. Using 138 control mouse liver samples from 28 studies analyzed with the TwinStrand Mouse Mutagenesis Panel, we performed variance component analysis and found that experiment-level variability exceeds within-experiment sample variability. To evaluate the impact of between-study heterogeneity, we simulated overdispersed binomial data informed by the observed variance components. Removing the most variable studies reduced overdispersion and improved control of the type 1 error rate. Our findings demonstrate that DS maintains appropriate type 1 error rates (~0.05) when study heterogeneity is limited and at least four samples per group are used. Under greater overdispersion, sample sizes of five or six per group may be needed to achieve comparable control of the type 1 error rate. These results underscore the importance of combining empirical and simulation-based approaches to evaluate and optimize the statistical performance of emerging genomic technologies.

Indexed as

Sequence Analysis, DNAAnimalsComputer SimulationLiverMiceMutagenesisMutagenicity TestsMutagensMutation RateMutagensduplex sequencingmutagenicity testingtype 1 error

Identifiers

PMID42304646
PMCPMC13272924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.